Deals

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035
ADC / XDCAdlai Nortye

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035

Adlai Nortye (NASDAQ: ANL) announced that it has separately entered into clinical trial collaboration and drug supply agreements with Eli Lilly and Company (NYSE: LLY) and Merck KGaA, Darmstadt, Germany…

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
mRNAStarna Therapeutics

Jiangsu Synthgene and Starna Therapeutics Join Forces in mRNA Technology Advancement

ADC / XDCEscugen

Shanghai Escugen Partners with InxMed for Global Development Rights to EZWi-Fit Platform

AICancer

MSD Partners with Owkin to Develop MSI-H Biomarker Screening for Cancers

AstraZenecaAZ

Sanofi Expands Oncology Portfolio with NK Cell Engager In-License from Innate Pharma

Show More